CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient ...

Operator: Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode. The call is being webcast live on the Investors section of ...

--Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell- derived cellular immunotherapies to patients ...

Scott Wolchko: Yes. We are working through that. I can think one of the strategies, quite honestly, with respect that we have heard, in speaking with folks in the field is that, in these early days, ...

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning ...